Treatment of moderately to severely active Crohn's disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies.
Treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.
Use of infliximab (subcutaneous) should be reserved for those whom attending a clinical setting to receive infliximab (intravenous) proves to be a barrier to receiving treatment.
The patient and/or carer must receive proper training in subcutaneous injection technique if their specialist determines that it is appropriate to self-inject and with medical follow- up as necessary. Suitability of the patient for subcutaneous home use should be assessed and patients should be advised to inform their healthcare professional if they experience symptoms of an allergic reaction before administering the next dose. Patients should seek immediate medical attention if developing symptoms of serious allergic reactions
Also approved for S.C use - see https://www.lancsmmg.nhs.uk/medicines-library/infliximab-second-line-biologic-for-moderate-to-severe-active-ulcerative-colitis/